EVALUATION OF TRANSITION EFFICACY TO ANGIOTENSINE CONVERTING ENZYME INHIBITORS IN PATIENTS WITH INSUFFICIENT BLOOD PRESSURE CONTROL. THE RESULTS FROM REGIONAL PROGRAM “SARA”
https://doi.org/10.15829/1560-4071-2017-3-85-90
Abstract
Aim. To evaluate an additional antihypertension efficacy and tolerability of perindopril comparing to sartans in real clinical practice.
Material and methods. The study had been designed, that included 208 patients. Main inculsion criteria was arterial hypertension (AH) with insufficient blood pressure (BP) control on treatment by angiotensine receptor blocker (ARB) as monotherapy, with 1 or 2 risk factors by SCORE system and on treatment by a free ARB combination with other drugs classes. In inclusion to program, instead of ARB perindopril (Prestarium A) 10 mg was added or its disperging form 10 mg in the morning. Duration of program lasted for 3 months. The evaluation of BP decrease was done, as the target BP levels reach and treatment response.
Results. On treatment with perindopril, in 2 weeks there was statistically significant (p<0,05) decrease of BP, and this positive dynamics remained for all follow-up period. Target BP was reached in 42,4% patients. Assessment of efficacy criteria of SARA program revealed in all participants BP decrease from baseline level, with median of systolic BP decrease as 30 [25;42] mmHg, diastolic — 20 [10;20] mmHg. Target BP was reached in 42,4%.
Conclusion. Transition from non-effective former sartans treatment to perindopril makes for successful BP control with high treatment tolerance. Such approach can be recommended for patient’s management in real clinical practice.
About the Authors
S. S. Yakushin
RyazSMU of the Ministry of Health
Russian Federation
Russian Federation
S. V. Seleznev
RyazSMU of the Ministry of Health
Russian Federation
Russian Federation
References
1. Сhazova IE, Ratova LG, Boytsov SA, et al. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hypertension and Society of Cardiology of the Russian Federation. Sistemnye gipertenzii 2010; 3: 5-26. Russian (Чазова Е. И., Ратова Л. Г., Бойцов С. А. и др. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные гипертензии 2010, 3: 5-26).
2. Loukianov MM, Boytsov SA, Yakushin SS. Concomitant cardiovascular diseases and antihypertensive treatment in outpatient practice (by the RECVASA registry data). Rational Pharmacotherapy in Cardiology 2016; 1: 4-15. Russian (Лукьянов М. М., Бойцов С. А., Якушин С. С. и др. Сочетанные сердечно-сосудистые заболевания и антигипертензивное лечение у больных с артериальной гипертонией в амбулаторно-поликлинической практике (по данным регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии 2016; 1: 4-15).
3. Chazova IE, Zhernakova YuV, Oschepkova EV. Prevalence of risk factors for cardiovascular diseases in the Russian population of patients with hypertension. Cardiology 2014; 10: 4-12. Russian (Чазова И. Е., Жернакова Ю. В., Ощепкова Е. В. и др. Распространенность ФР сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 10: 4-12).
4. Lewington S, Clarke R, Qizilbash N, et al. Age specific relevance of usual blood pressure to vascular mortality: meta-analyses of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1129-34.
5. Kukes VG. Clinical pharmacology. 4edition. Moscow: Geotar-Media, 2008. p 395. Russian (Кукес В. Г. Клиническая фармакология Изд. 4-е. М.: ГЭОТАР-Медиа, 2008. c. 395).
6. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebocontrolled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
7. Strauss MH, Hall AS. Do angiotensin receptor blockers increase risk of myocardial infarction? Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling paradox. Circulation 2006; 114: 828-54.
8. The ADVANCE Collaborative Group: Rationale and design of the ADVANCE Study: a randomised trial of blood pressure lowering and intensive glucose control in high risk individuals with type 2 diabetes mellitus. J. Hypertens 2001; 19: 21-8.
9. Ranadive SA, Chen AX, Serajuddin AT. Relative lipophilicities and structuralpharmacological considerations of various angiotensinconverting enzyme inhibitors. Pharm Res 1992; 9 (11): 1480-6.
10. The PROGRESS Collaborative Group. Randomised trial of a perindopril-based bloodpressure-lowering among 6105 individuals with previous stroke or transientischaemic attack. Lancet 2001; 358: 1033-41.
11. Lopez-Sendon J, Swedberg K, McMurray JJ, et al. Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur. Heart J. 2004; 25: 1454-70.
Review
For citations:
Yakushin S.S., Seleznev S.V. EVALUATION OF TRANSITION EFFICACY TO ANGIOTENSINE CONVERTING ENZYME INHIBITORS IN PATIENTS WITH INSUFFICIENT BLOOD PRESSURE CONTROL. THE RESULTS FROM REGIONAL PROGRAM “SARA”. Russian Journal of Cardiology. 2017;(3):85-90. (In Russ.) https://doi.org/10.15829/1560-4071-2017-3-85-90
Views:
4281
Email this article 